BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Y, Zhu Y, Hu S, Pan X, Bawa FC, Wang HH, Wang DQ, Yin L, Zhang Y. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease. Mol Metab 2021;51:101244. [PMID: 33930596 DOI: 10.1016/j.molmet.2021.101244] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Shen Y, Liang X, Zheng H, Zhang Y. MicroRNAs as Biomarkers and Therapeutic Targets for Nonalcoholic Fatty Liver Disease: A Narrative Review. Clin Ther 2023:S0149-2918(23)00037-1. [PMID: 36841739 DOI: 10.1016/j.clinthera.2023.02.001] [Reference Citation Analysis]
2 Atic AI, Thiele M, Munk A, Dalgaard LT. Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2023;324:C588-602. [PMID: 36645666 DOI: 10.1152/ajpcell.00253.2022] [Reference Citation Analysis]
3 Sarangi R, Mishra S, Das S, Mishra A. Nonalcoholic Fatty Liver Disease and MicroRNAs: A Weighty Consideration. Biomed Biotechnol Res J 2023;7:1. [DOI: 10.4103/bbrj.bbrj_319_22] [Reference Citation Analysis]
4 Guha S, Sesili S, Mir IH, Thirunavukkarasu C. Epigenetics and mitochondrial dysfunction insights into the impact of the progression of non-alcoholic fatty liver disease. Cell Biochem Funct 2023;41:4-19. [PMID: 36330539 DOI: 10.1002/cbf.3763] [Reference Citation Analysis]
5 Petito G, Giacco A, Cioffi F, Mazzoli A, Magnacca N, Iossa S, Goglia F, Senese R, Lanni A. Short-term fructose feeding alters tissue metabolic pathways by modulating microRNAs expression both in young and adult rats. Front Cell Dev Biol 2023;11:1101844. [PMID: 36875756 DOI: 10.3389/fcell.2023.1101844] [Reference Citation Analysis]
6 Wang Z, Zhu Y, Xia L, Li J, Song M, Yang C. Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a. Nutrients 2022;15. [PMID: 36615779 DOI: 10.3390/nu15010121] [Reference Citation Analysis]
7 Mukherjee AG, Wanjari UR, Gopalakrishnan AV, Katturajan R, Kannampuzha S, Murali R, Namachivayam A, Ganesan R, Renu K, Dey A, Vellingiri B, Prince SE. Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs. Cells 2022;11. [PMID: 36552725 DOI: 10.3390/cells11243959] [Reference Citation Analysis]
8 Yang TY, Yu MH, Wu YL, Hong CC, Chen CS, Chan KC, Wang CJ. Mulberry Leaf (Morus alba L.) Extracts and Its Chlorogenic Acid Isomer Component Improve Glucolipotoxicity-Induced Hepatic Lipid Accumulation via Downregulating miR-34a and Decreased Inflammation. Nutrients 2022;14. [PMID: 36432495 DOI: 10.3390/nu14224808] [Reference Citation Analysis]
9 Rusu I, Pirlog R, Chiroi P, Nutu A, Puia VR, Fetti AC, Rusu DR, Berindan-Neagoe I, Al Hajjar N. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. Int J Mol Sci 2022;23:12370. [PMID: 36293225 DOI: 10.3390/ijms232012370] [Reference Citation Analysis]
10 Sun H, Seok S, Jung H, Kemper B, Kemper JK. Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice. Mol Metab 2022;66:101603. [PMID: 36126896 DOI: 10.1016/j.molmet.2022.101603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang Y, Zhou F, Li M, Zhang Y, Li N, Shao L. MiR-34a-5p promotes hepatic gluconeogenesis by suppressing SIRT1 expression. Exp Cell Res 2022;:113336. [PMID: 36058294 DOI: 10.1016/j.yexcr.2022.113336] [Reference Citation Analysis]
12 Hochreuter MY, Dall M, Treebak JT, Barrès R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab 2022;:101581. [PMID: 36028120 DOI: 10.1016/j.molmet.2022.101581] [Reference Citation Analysis]
13 Yu C, Chen J, Ren J. Advances of microRNAs in regulating mitochondrial function: new potential application in NAFLD treatment. Mol Biol Rep 2022. [PMID: 35612781 DOI: 10.1007/s11033-022-07503-0] [Reference Citation Analysis]
14 Zhang C, Yang M. Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. Front Med (Lausanne) 2021;8:789859. [PMID: 34869507 DOI: 10.3389/fmed.2021.789859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Yu MH, Hung TW, Wang CC, Wu SW, Yang TW, Yang CY, Tseng TH, Wang CJ. Neochlorogenic Acid Attenuates Hepatic Lipid Accumulation and Inflammation via Regulating miR-34a In Vitro. Int J Mol Sci 2021;22:13163. [PMID: 34884968 DOI: 10.3390/ijms222313163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech 2021;14:dmm049173. [PMID: 34850865 DOI: 10.1242/dmm.049173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bazrgar M, Khodabakhsh P, Prudencio M, Mohagheghi F, Ahmadiani A. The role of microRNA-34 family in Alzheimer's disease: A potential molecular link between neurodegeneration and metabolic disorders. Pharmacol Res 2021;172:105805. [PMID: 34371173 DOI: 10.1016/j.phrs.2021.105805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]